The discovery of molecules such as PD-1 on T cells has paved the way for tapping the immune system in combating cancer. The advancement of technologies and understanding of the interplay of various immune cells exposes the role of new immune cell mechanisms in cancer. The research around the tumor microenvironment (TME) has led to the discoveries of immune suppressive mechanisms such as Myeloid Derived Suppressor Cells (MDSCs), Tumor Associated Macrophages (TAMs) and Regulatory T cells (Tregs). Further studies have highlighted the role of the tumor stroma and extracellular matrix (ECM) towards the resistance of tumors to immunotherapy. Immuno-oncology represents a major aspect of our business and we have invested heavily in the development of novel cell lines and assay platforms to help our partners screen for the right drug candidates early in the development process.
Relevant assays for this disease: